Table 5 Comparison of demographic and clinical characteristics of participants recruited pre-legalization with and without cannabis urine screen data
Characteristic | Total pre-legalization sample (n = 602) | Pre-legalization sample with cannabis urine drug screens followed through post-legalization period (n = 199) |
|---|---|---|
Age in years; mean (SD) | 38.9 (10.4) | 40.6 (11.1) |
Male sex; n (%) | 343 (57) | 97 (48.7) |
Type of MAT; n (%) | ||
→ Methadone | 498 (82.9) | 171 (85.9) |
→ Buprenorphine | 103 (17.1) | 28 (14.1) |
Dose (mg/day); median (IQR) | ||
→ Methadone | 65 (61) | 75 (63) |
→ Buprenorphine | 12 (8) | 12 (7) |
Length of time in treatment (years); median (IQR) | 2 (4.9) | 3 (5) |
Opioid abstinencea; n (%) | 176 (29.2) | 66 (33.2) |
Percentage of opioid-positive urine drug screens amongst non-abstainersa; mean (SD) | 21.1 (23.3) | 16.5 (18.7) |
Self-reported cannabis use; n (%) | 330 (54.8%) | 111 (55.8) |
Days of use in the last 30 days amongst users; median (IQR) | 30 (16) | 30 (15) |